These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33493633)

  • 1. Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    Francolini G; Borghesi S; Fersino S; Magli A; Jereczek-Fossa BA; Cristinelli L; Rizzo M; Corvò R; Pappagallo GL; Arcangeli S; Magrini SM; D'Angelillo RM
    Crit Rev Oncol Hematol; 2021 Mar; 159():103235. PubMed ID: 33493633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
    Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
    Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
    Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    Su X; Dong C; Liao W; Liu W
    World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
    Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
    Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.
    Qiu J; Zhang H; Xu D; Li L; Xu L; Jiang Y; Wen T; Lu S; Meng F; Feng L; Shu X
    J Oncol; 2022; 2022():7306198. PubMed ID: 35607328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
    Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
    Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
    Mathieu R; Lucca I; Klatte T; Babjuk M; Shariat SF
    Curr Opin Urol; 2015 Sep; 25(5):476-82. PubMed ID: 26125510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer].
    Wang JF; Zhou XF; Fang DB; Wu ZM; Ding ZS; Chen X; Liu NB
    Zhonghua Yi Xue Za Zhi; 2018 May; 98(20):1614-1616. PubMed ID: 29886656
    [No Abstract]   [Full Text] [Related]  

  • 19. Identifying Optimal Candidates for Trimodality Therapy among Nonmetastatic Muscle-Invasive Bladder Cancer Patients.
    Ran S; Yang J; Hu J; Fang L; He W
    Curr Oncol; 2023 Nov; 30(12):10166-10178. PubMed ID: 38132374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis.
    Ding H; Fan N; Ning Z; Ma D
    Front Oncol; 2020; 10():564779. PubMed ID: 33154943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.